Bharat Biotech

Booster dose of vaccine, COVAXIN® (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay

ओमीक्रॉन से निपटने के लिए बूस्टर डोज़ की तैयारी कर रहा है भारत

The peer-review of COVAXIN phase III clinical trial data in The Lancet, an authoritative voice in global medicine validates our commitment to data transparency

WHO will expedite global access and availability of COVAXIN worldwide

Bharat Biotech’s ROTAVAC 5D Receives WHO Prequalification

India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%

India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%

Post Budget Reaction from India Inc.

A momentous achievement for India!

There was an urgent need